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Aims: Energy-based devices using radiofrequency and laser technologies have
gained popularity as therapies for vaginal atrophy, urinary incontinence, and vaginal
prolapse. They have been promoted by cosmetic and aesthetic industries for vaginal
“laxity” and vaginal “rejuvenation,” both of which are undefined conditions and
terms. This article aims to review the current available literature and its quality on this
emerging technology.
Methods: An international panel of gynaecologists, urogynaecologists, and
urologists undertook a review of the available published literature, identifying
articles, guidance, and society statements on the use vaginal energy-based devices.
Results: There is currently no formal guidance for the use of vaginal energy based
therapies. No randomized controlled trials have been published. No comparative
studies to existing treatment has been carried out. Studies suggest that vaginal laser
can be used in the treatment of vaginal prolapse or “vaginal laxity” and stress urinary
incontinence with no quality evidence supporting the use of the therapy for vaginal
atrophy or lichen sclerosis.
Conclusions: This international group propose that whilst there remains a paucity of
good quality data describing the safety, benefits, and appropriate use of vaginal
radiofrequency or laser treatments in gynaecology and urogynaecology, a consensus
best practice document by an established scientific community needs to be developed.
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1 | INTRODUCTION
Energy-based devices and laser technology have FDA approval
for incision, excision, ablation, vaporization, coagulation, and
hemostasis of various soft tissues.The technology is usedbyboth
medical and surgical specialities including dermatology, plastic
surgery, podiatry, otolaryngology, gynaecology, neurosurgery,
orthopaedics, thoracic surgery, dental and oral surgery, and
genitourinary surgery.”1,2 More recently, cosmetic or “rejuve-
nating” non-surgical procedures utilizing these same radio-
frequency and laser technologies are growing in popularity.
Vaginal “rejuvenation” is a descriptive non-scientific term
used by the medical device and cosmetic industries for non-
surgical vaginal cosmetic procedures or therapies. Its use is
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promoted to treat symptoms related to menopause, urinary
incontinence, or to improve sexual function.3 The procedure
has alternatively been labeled as cosmetic gynaecology, “re-
virgination” surgery, female genital plastic surgery, designer
vaginal surgery, and G-spot amplification. These non-specific
names have been used interchangeably with no clear
standardized or scientific definition or procedure protocol.
They also lack clarity and are not recognized by influential
scientific communities or the Food and Drug Administration
(FDA),who to date, have not cleared or approved energy based
devices for any of the aforementioned vaginal procedures.3–8
Vaginal rejuvenation is advertised as a treatment for a
diverse range of vaginal changes secondary to estrogen
deficiency and aging (eg, vaginal atrophy and dryness),
childbirth (eg, vaginal laxity or prolapse symptoms) as well as
symptoms of vaginal itching, dyspareunia, pain during
urination, and decreased sexual sensation. The therapy
commonly utilizes radiofrequency or laser energy with a
regime of repeated treatments twice or thrice every 4-6weeks.
The average cost of each treatment ranges between £400 and
£1000. The therapy has a broad range of treatment aim for
example to “tighten” the vagina, to treat vaginal atrophy, to
eliminate dryness and/or itching, to stop incontinence, to treat
pain during sexual intercourse or during micturition, to
improve the sexual sensation.
Concerns regarding the use of laser and radiofrequency
are not new and have previously been raised by several
authors9,10 and international societies, including the Ameri-
can College of Obstetricians and Gynecologists (ACOG),11
the Society of Obstetricians and Gynecologists of Canada,12
the International Society for the Study of Vulvovaginal
Disease (ISSVD),13 and the North American Menopause
Society (NAMS). Despite recent publications alluding to
subjective improvements in vaginal itching, dryness, sexual
function, dyspareunia, and vaginal laxity, many studies have
demonstrated contradictory and hard to explain results.8,14
Many studies reporting vaginal laser outcomes are industry
sponsored, retrospective, non-randomized, short-term, lacking
a control group, and utilize non-standardized or validated
outcome measures with risks of significant bias. Omissions of
reported complications is of concern and should not be ignored.
Appropriately the FDA have therefore cautioned women
considering vaginal “rejuvenation” procedures. In a supporting
SafetyCommunication issued on30th July 2018, theFDAstate
that “these products have serious risks and do not have
adequate evidence to support their use for these purposes. We
are deeply concerned women are being harmed.”3
The FDA urges women to heed their warnings, they have
emphasized that women who are considering energy based
vaginal procedures utilising radiofrequency and/or laser to
treat the described symptoms above can lead to serious
adverse events. Potential complications of vaginal burns,
scarring, dryness, infection, altered sensation, dyspareunia,
adhesions, scarring, recurring pain, or vaginal stenosis over
time2 may occur. These could cause sexual dysfunction or
worsening quality of life as a result of radiofrequency and
laser vaginal procedures for vaginal “rejuvenation.” In
July 2018, the FDA Commissioner Scott Gottlieb, M.D.
reported on these adverse effects following an FDA review;
“. . . the full extent of the risks is unknown. But these reports
indicate these procedures can cause serious harm.”15 The
FDA informed the public of alarming results following
vaginal laser and energy-based therapies, these are available
for public review on the FDA's Adverse Event Report
Databases.
Given this pertinent advice from the FDA, it is indisputable
that despite promising availability of short-term data, more
robust, sham-controlled, and knowledge of longer-term out-
comes are still needed. There is still a lack of randomized
control trials (RCTs) assessing the efficacy and safety of
energy based devices for vaginal “rejuvenation.” Many
unanswered questions still remain for example the long term
impact on tissues and on adjacent nerves, vessels, bladder,
rectum, etc is unknown. The unregulated use of vaginal laser
will make it difficult to assess any long-term impact. There
may be an effect on surgical dissection and treatment outcomes
in the future if women eventually seek appropriate reconstruc-
tive pelvic or anti-incontinence surgery.
Ideally any future RCTs should compare treatment with a
sham treatment to assess the impact of the placebo effect. To
provide context, data has shown that 70% of the improvement
outcome for women undergoing treatment for sexual
dysfunction, is the result of placebo treatment.16 It is
therefore expected that women seeking vaginal rejuvenation
for sexual dysfunction would find improvement, even in the
absence of a biological effect.
Vaginal laser therapy has also been used for defined
gynaecological conditions, for example, treatment of vulvo-
vaginal atrophy. However assertions for vaginal rejuvenation
by laser is not sustained by histological evidence or long term
studies and is misleading. Women can alternatively be
effectively and safely treated with topical oestrogen even in
women with previous cancer or are unable to use systemic
hormone replacement therapy.17,18 Similarly, claims that
vaginal laser is a treatment option for womenwith vulvodynia
and lichen sclerosus is again not supported by scientific
evidence, lacks biological plausibility, and can cause
potential harm. The appeal of vaginal laser treatment as an
office procedure for female pelvic organ prolapse, the so
called “vaginal relaxation syndrome” and stress urinary
incontinence has also been explored.19–29 There is minimal
published data with the recurring theme of paucity of good
quality evidence in the form of multi-center randomized
placebo-controlled trials, which is concerning.
If treatment with laser/energy devices are attractive to
both the woman and clinician, in the absence of strong
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scientific evidence on the clinical role of laser treatment,
appropriate pretreatment counseling addressing potential and
known risks and benefits is mandatory. Established treatment
alternatives should also be offered. We strongly believe that
physicians have an ethical responsibility to provide their
patients with accurate information regarding the efficacy
and safety of innovative practices, especially when using/
promoting new devices for treatments whose efficacy and
safety are still not completely known.17
In the informed decision-making process relational
factors should be considered, as sexuality in postmenopausal
women is a complex mosaic of physical, psychological,
socioeconomic, and cultural factors. An approach simply
focused to the “vaginal mucosa” is limited and insufficient.5
2 | CONCLUSIONS
The FDA has not yet determined whether it is safe or practical to
use energy-based devices such as lasers for “rejuvenation”
procedures or the aforementioned described symptoms and
gynaecological conditions.1,2,5 Until further robust scientific data
emerges, this technology should be considered experimental.
We believe that the use of laser and radiofrequency energy
based devices for the treatment of lichen sclerosus, vulvodynia,
urinary incontinence, sexual dysfunction, pelvic organ prolapse,
urinary tract infections, vulvovaginal atrophy, or for vaginal
“rejuvenation,” should only be used within the research setting
of properly designed clinical trials. Patients enrolled in these
studies shouldbeappropriately andclearly counseled, consented
and followed up. The follow-up protocol should be sufficiently
long enough to establish the long-term effects of vaginal laser
and radiofrequency. It remains unknown if any negative impact
may become evident several months or years after treatment or
following repeated treatments.
If patients are determined to undergo vaginal “rejuvenation”
as a therapy outside of a trial, it is the clinician's ethical
responsibility to inform patients about the lack of data and
uncertainty on efficacy and safety of the therapy and provide
known information about potential complications. Arrangements
for clinical governance, consent, and audit should be made.
ORCID
Giuseppe Alessandro Digesu http://orcid.org/0000-0002-
3914-8147
REFERENCES
1. U.S. Food and Drug Administration. 510(k) Summary for RevLite
Q-Switched Nd:YAG Laser System [letter]. Silver Spring
(MD): FDA; 2014. Available at: http://www.accessdata.fda.gov/
cdrh_docs/pdf13/k133254.pdf. Retrieved May 19, 2016.
2. Committee on Gynecologic Practice, American College of
Obstetricians and Gynecologists. ACOG committee opinion
No.378: “Vaginal rejuvenation” and cosmetic vaginal procedures.
Obstet Gynecol 2007;110:737–738.
3. FDA Warns Against Use of Energy-Based Devices to Perform
Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures: FDA
Safety Communication. https://www.fda.gov/MedicalDevices/
Safety/AlertsandNotices/ucm615013.htm.
4. Streicher LF. Vulvar and vaginal fractional CO2 laser treatments
for genitourinary syndrome of menopause. Menopause. 2018;25:
571–573.
5. U.S. Food and Drug Administration. Re: trade/device name: DEKA
SmartXide2 Laser System [letter]. Silver Spring (MD): FDA; 2014.
Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf13/
k133895.pdf. Retrieved May 19, 2016.
6. Vieira-Baptista P, Damaser M, Digesu A, Marchitelli C, Preti M,
Stockdale C. To the Editor.Menopause. July 2018 1. https://doi.org/
10.1097/GME. 0000000000001165.
7. Fractional laser treatment of vulvovaginal atrophy and U.S. Food




8. Fractional microablative CO2 laser in breast cancer survivors
affected by iatrogenic vulvovaginal atrophy after failure of
nonestrogenic local treatments: a retrospective study: erratum.
Menopause. 2018;25:1169.
9. Digesu GA, Swift S. Laser treatment in urogynaecology and
the myth of the scientific evidence. Int Urogynecol J. 2017;28:
1443–1444.
10. Singh A, Swift S, Khullar V, Digesu GA. Laser vaginal
rejuvenation: not ready for prime time. Int Urogynecol J. 2015;
26:163–164.
11. ACOG committee opinion No. 378: vaginal “rejuvenation” and
cosmetic vaginal procedures. Obstet Gynecol. 2007;110:737–738.
12. Walter J-E, Larochelle A. No. 358-Intravaginal laser for genitouri-
nary syndrome of menopause and stress urinary incontinence.
J Obstet Gynaecol Canada. 2018;40:503–511.
13. Vieira-Baptista P, Almeida G, Bogliatto F, et al. International
society for the study of vulvovaginal disease recommendations
regarding female cosmetic genital surgery. J Low Genit Tract Dis
2018;22:415–434.
14. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-
blind, placebo-controlled clinical trial for evaluating the efficacy of
fractional CO2 laser compared with topical estriol in the treatment
of vaginal atrophy in postmenopausal women. Menopause. 2018;
25:21–28.
15. Statement from FDA Commissioner Scott Gottlieb, M.D., on
efforts to safeguard women's health from deceptive health
claims and significant risks related to devices marketed for use
in medical procedures for “vaginal rejuvenation”. https://www.
fda.gov/newsevents/newsroom/pressannouncements/ucm615130.
htm
16. Weinberger JM, Houman J, Caron AT, et al. Female Sexual
Dysfunction and the Placebo Effect. Obstet Gynecol. 2018;132:
453–458.
17. ACOG committee on ethics. ACOG committee opinion No. 352:
innovative practice: ethical guidelines. Obstet Gynecol. 2006;108:
1589–1595.
DIGESU ET AL.. | 3
18. Rueda C, Osorio AM, Avellaneda AC, Pinzón CE, Restrepo OI.
The efficacy and safety of estriol to treat vulvovaginal atrophy
in postmenopausal women: a systematic literature review.
Climacteric. 2017;20:321–330.
19. Gaspar A, Addamo G, Brandi H. Vaginal fractional CO 2 laser: a
minimally invasive option for vaginal rejuvenation. Am J Cosmet
Surg. 2011;28:156–162.
20. Ogrinc UB, Senčar S, Lenasi H. Novel minimally invasive laser
treatment of urinary incontinence in women. Lasers Surg Med.
2015;47:689–697.
21. Fistonić N, Fistonić I, Guštek ŠF, et al. Minimally invasive,
non-ablative Er:YAG laser treatment of stress urinary incontinence
in women—a pilot study. Lasers Med Sci. 2016;31:635–643.
22. Fistonić N, Fistonić I, Lukanovič A, Findri G, Sorta Bilajac Turina
I, Franić D. First assessment of short-term efficacy of Er:YAG laser
treatment on stress urinary incontinence in women: Prospective
cohort study. Climacteric. 2015;18:37–42.
23. Pardo JI, Solà VR, Morales AA. Treatment of female stress urinary
incontinence with Erbium-YAG laser in non-ablative mode. Eur J
Obstet Gynecol Reprod Biol. 2016;204:1–4.
24. Gaspar A, Brandi H. Non-ablative erbium YAG laser for the
treatment of type III stress urinary incontinence (intrinsic sphincter
deficiency). Lasers Med Sci. 2017;32:685–691.
25. Gambacciani M, Torelli MG, Martella L, et al. Rationale and
design for the vaginal erbium laser academy study (Velas):
An international multicenter observational study on genitourinary
syndrome of menopause and stress urinary incontinence.
Climacteric. 2015;18:43–48.
26. Gaviria JE, Lanz JA. Laser vaginal tightening (LVT)—evaluation
of a novel noninvasive laser treatment for vaginal relaxation
syndrome. J Laser Heal Acad Artic J LAHA. 2012;1:59–66.
27. Bizjak Ogrinc U, Sencar S, Non-surgical minimally invasive Er:
YAG laser treatment for higher-grade cystocele. NDP 373, 38th
Annual IUGA Meeting, Dublin, Ireland; May 28th–June 1st, 2013.
28. Bizjak-Ogrinc U, Sencar S, Vizintin Z. #178 3 years follow-up of
pelvic organ prolapse treated with Er:YAG laser. 37th American
Society for Laser Medicine and Surgery, San Diego, USA 5-9 April
2017.
29. da Silva Lara LA, Useche B, Rosa e Silva JC, et al. Sexuality during
the climacteric period. Maturitas. 2009;62:127–133.
How to cite this article: Digesu GA, Tailor V, Preti
M, et al. The energy based devices for vaginal
“rejuvenation,” urinary incontinence, vaginal
cosmetic procedures, and other vulvo-vaginal
disorders: An international multidisciplinary expert
panel opinion. Neurourology and Urodynamics.
2019;1–4. https://doi.org/10.1002/nau.23927
4 | DIGESU ET AL.
